Monk Fruit vs Erythritol

If you have bought a tub of “monk fruit sweetener”, you have very likely bought erythritol. Monk fruit extract is so intense, 100 to 250 times sweeter than sugar, that a usable spoonful has to be mostly something else, and that something is very often erythritol. So comparing the two is mostly a way of understanding one product: which part of it sweetens, which part you are actually eating, and where each part’s open questions lie. Both have them. Monk fruit’s are about an unfinished safety file; erythritol’s are about digestion and a cardiovascular signal.

At a Glance

Every row below comes from our two sourced records, the same ones the cards at the foot of this page show. Each figure links to the document it came from and the date we last checked it; open “Note” for the qualifications that go with it. Where a record has nothing sourced for a row, the cell says so rather than filling the gap.

Attribute	Monk Fruit	Erythritol
Sweetness	100–250× sweeter than sugarUS Food and Drug Administration regulatory checked 30 Aug 2026 Note A MULTIPLE, not a fraction — see the header warning. CORRECTED 2026-08-30 from an earlier 100-400 band: FDA gives 100-250 for the EXTRACT ("SGFE, depending on the mogroside content, is reported to be 100 to 250 times sweeter than sugar"), while the ~250 figure in the literature describes PURE mogroside V. Those are not in conflict once you separate extract from active compound, and the extract figure is the one that matters commercially. Potency tracks mogroside V content, which varies 2%-95% between grades.	60–80% of sugarEFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026 Note Specification band. Measured potency is concentration-dependent: 0.72 / 0.75 / 0.84 against 5 / 10 / 15% w/v sucrose (Wee 2018); 0.50-0.78 across 3-20% (Fujimaru 2012).
Calories	Negligible at use levelsUS FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026 Note Deliberately not stated as "0 kcal/g". No authority has assigned monk fruit extract a caloric factor the way FDA assigned erythritol 0 and allulose 0.4. What is documented is the exposure: mean SGFE intake up to 1.6 mg/kg bw/day, 90th percentile 4.2 mg/kg bw/day in healthy adults.	0 kcal per gramElectronic Code of Federal Regulations regulatory checked 29 Aug 2026
Net carbs	Subtracts in full — none of its grams countUS FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026 Note Applies to the EXTRACT ONLY. Reported mean dietary exposures are 0.58-1.52 mg/kg bw/day of mogroside V depending on subpopulation — milligrams, against grams for a bulk sweetener. For a retail blend, compute the carbohydrate from the bulking agent and treat the monk fruit as zero.	Subtracts in full — none of its grams countElectronic Code of Federal Regulations regulatory checked 29 Aug 2026 Note FDA assigns erythritol 0 cal/g, uniquely among polyols (all others 2.0-3.0). Glycaemic index 0.
Blood glucose	No meaningful glucose or insulin spike in healthy adults, acutelyTey SL, Salleh NB, Henry J, Forde CG; International… peer reviewed checked 31 Aug 2026 Note Tey et al. 2017, the only published human RCT of monk fruit sweetener itself (as opposed to its regulatory toxicology). 30 healthy men, randomised crossover, four 65 g-sucrose-equivalent preloads (aspartame, monk fruit, stevia, sucrose). Monk fruit, stevia and aspartame all produced significantly lower postprandial glucose and insulin than sucrose, with no meaningful spike above baseline for any of the three. THE MORE INTERESTING FINDING: ad libitum lunch intake after the non-nutritive-sweetener preloads was significantly HIGHER than after sucrose — compensatory eating largely offset the calories saved at the preload, leaving total daily energy intake unchanged across all four arms. Read as evidence about the preload only, not as evidence the sweetener itself changes appetite regulation days or weeks out — one meal, one measurement.	0 (glucose = 100)Livesey G, Nutrition Research Reviews 16:163-191 peer reviewed checked 29 Aug 2026 Note Mean 0, SD 17 across 4 studies (glucose = 100). Insulinaemic index 2. The SD is large relative to the mean: this is "no detectable effect", not a precise zero.
Acceptable daily intake	Temporary ADI 0-10 mg/kg bw/day, as mogroside V (JECFA, 2026)JECFA (FAO/WHO) regulatory checked 27 Oct 2026 Note JECFA, 102nd meeting (2026): "The Committee established a temporary ADI of 0-10 mg/kg bw per day, expressed as mogroside V, based on a NOAEL of 2144 mg/kg bw per day for mogroside V, the highest dose tested in a 52-week rat study and the application of a 200-fold uncertainty factor." In the same evaluation JECFA took a conservative estimate of the highest dietary exposure for children, 38 mg/kg bw/day, and concluded it "exceeds the temporary ADI by approximately four-fold, which would pose a potential safety concern under the proposed uses and proposed maximum levels". JECFA noted that estimate rests on proposed Codex (GSFA) food categories and maximum levels, not on measured intakes; FDA's modelling for US use (GRN 706, see dietary_exposure_mg_per_kg_day) is far lower, a 1.52 mg/kg bw/day mean for diabetic children. To complete the evaluation JECFA requires, by the end of 2029, a reproductive toxicity study that evaluates the reproductive capacity of the F1 generation, and revised proposed uses and maximum levels. History: JECFA put monk fruit extract on its 2016 agenda and removed it because no data were submitted; EFSA (2019) could not set an ADI because the toxicity database was insufficient (see safety_signal).	EU 0.5 g per kg body weight per dayEFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026 Note EFSA pooled NOAELs for diarrhoea from 10 human studies: range 0.51-1.0 g/kg bw, median 0.75. EFSA adopted the lower bound, 0.5 g/kg bw/day, as its first numerical ADI for erythritol (Dec 2023) and found children's 95th-percentile intake already exceeds it.
Digestive tolerance	No sourced entry	0.5–1 g/kg in one sitting · EU limit 0.5 g/kg per dayEFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026 Note EFSA pooled NOAELs for diarrhoea from 10 human studies: range 0.51-1.0 g/kg bw, median 0.75. EFSA adopted the lower bound, 0.5 g/kg bw/day, as its first numerical ADI for erythritol (Dec 2023) and found children's 95th-percentile intake already exceeds it.
Browning	No sourced entry	NoneEuropean Commission regulatory checked 29 Aug 2026 Note Polyols do not participate in Maillard browning; the additive specification caps reducing substances at 0.3% as D-glucose.
Bulk contribution	NoneUS FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026 Note High-intensity sweetener used at milligram levels; contributes no volume, structure, browning or mouthfeel. Any product that fills a measuring cup is doing so with something else. This is why tabletop "monk fruit" is usually a blend.	BulkingEFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026 Note Used as a bulk sweetener, but a 1:1 weight swap under-sweetens because it delivers only 60-80% of sucrose sweetness.
Recrystallisation	No sourced entry	HighTyapkova et al. peer reviewed checked 29 Aug 2026 Note Low solubility relative to sucrose; recrystallises on cooling, which is the mechanism behind the gritty or sandy texture in baked goods and frozen desserts.
United States	GRAS by notificationUS FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026 Note Six "no questions" letters: GRN 301 (15 Jan 2010), 359 (11 Apr 2011), 522 (8 Dec 2014), 556 (5 Nov 2015), 629, and 706 (17 Aug 2017). FDA is explicit that such a letter "is not an affirmation that SGFE is GRAS under 21 CFR 170.35". Intended use excludes infant formula.	GRAS by notificationUS Food and Drug Administration regulatory checked 27 Oct 2026 Note Six FDA "no questions" letters, per FDA's GRAS Notice Inventory (checked 2026-10-27): GRN 76 (closed 2001-09-11), 208 (2007-01-25), 382 (2011-11-21), 401 (2012-03-22), 789 (Cargill, 2019-02-20) and 1296 (Shandong Starlight So True, 2026-04-07), the last for erythritol "produced through fermentation of glucose by Yarrowia lipolytica". CORRECTED 2026-10-27: this note previously said six letters ran from GRN 76 through GRN 789, which is five. The production organism now varies by supplier, so prose naming only Moniliella is incomplete. Intended uses in GRN 1296 exclude infant formula and USDA-regulated products.
European Union	Not authorised as a food; only decoctions are exempt from needing authorisationEuropean Commission, Directorate-General for Health and Food Safety —… regulatory checked 31 Aug 2026 Note CORRECTED 2026-08-31 by two independent sessions running concurrently, reconciled here after a file-write race. This record previously said "Partially authorised", citing Commission Implementing Regulation (EU) 2024/2345 of 7 October 2024 as having authorised an aqueous monk fruit extract as a novel food, taken from Kaim 2025 (a peer-reviewed review). THAT IS WRONG, and it was wrong in the paper it came from. WHAT IS ACTUALLY TRUE, per the European Commission Novel Food Catalogue entry for Siraitia grosvenorii (updated 3 October 2024, source eucatalogue): the FRUIT and its extracts are classified NOVEL FOOD — "not consumed in the EU to a significant degree as a food before 15 May 1997", so "a pre-market authorisation in accordance with Regulation (EU) 2015/2283 is required before it can be placed as food on the EU market" — and no such authorisation has been granted. SEPARATELY, monk fruit DECOCTIONS are classified NOT NOVEL, following a determination by the Irish competent authority (FSAI) under Commission Implementing Regulation (EU) 2018/456, on the basis that decoctions were consumed in the Union before 15 May 1997. A not-novel determination means authorisation is NOT REQUIRED for decoctions specifically; it is not itself an authorisation, and it does not cover purified mogroside V or solvent extracts. Likely origin of the error: the decoction not-novel determination was catalogued in early October 2024 and got telescoped, somewhere in the citation chain, into an "authorising regulation of 7 October 2024" for the extract. Independently corroborated five ways: (1) the ELI lookup for reg_impl:2024:2345:oj returns "No results found"; (2) document number 2024/2345 does resolve on EUR-Lex, but to an unrelated OJ C-series item — a European Investment Bank Deputy Chief Executive vacancy notice published 21 March 2024 — with zero mention of Siraitia, monk fruit or novel food, which is why CELEX 32024R2345 (R for Regulation) 404s; (3) an EUR-Lex advanced search of every Commission Implementing Regulation published in October 2024 returns zero matches for "Siraitia" (the two novel-food authorisations that month were vitamin D2 mushroom powder and magnesium L-threonate); (4) the consolidated Union list of novel foods (Reg (EU) 2017/2470) contains zero occurrences of "Siraitia", "grosvenorii", "monk fruit" or "mogroside" — checked by full-text search of the entire consolidated Annex across three separate consolidated versions (2024-11-07, 2026-07-02, 2026-08-10 — see unionlist2026), with presence checks on known unrelated entries (astaxanthin, krill, chia) confirming each render was complete, not truncated; (5) kaim2025's own bibliography entry for the regulation cites "Off. J. Eur. Union. 2024;L 279:25–28", and that citation also fails to resolve on EUR-Lex ("the requested document does not exist") — the paper cites no distinct EFSA reference for the "2024 EFSA opinion" it says underpins the authorisation either; its footnotes for that claim point only to the 2019 additive opinion and an FSAI page about decoction status. Practical position: monk fruit EXTRACT cannot lawfully be placed on the EU market as a food — neither via the additive route (EFSA found the 2019 toxicology dossier insufficient; no ADI) nor via the novel-food route (no authorisation exists). A DECOCTION is a different product with a different, more permissive answer. The claim of a further additive application accepted for EFSA assessment with public consultation opened April 2026 is retained from kaim2025 but was NOT independently re-verified this pass — treat it as less solid than the findings above, which are.	Authorised, E 968EFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026 Note VERIFIED DIRECTLY against the EU Food Additives register, 2026-08-31 — do not confuse the two authorisation layers. The substance-specific listing for erythritol shows only ONE category (14.1.4, flavoured drinks, as a flavour enhancer, ML 16000 mg/l, energy-reduced/no-added-sugar only, under Reg (EU) 2015/1832) — reading only that would wrongly suggest erythritol is authorised for almost nothing. The real authorisation is broader: erythritol is a member of GROUP IV, POLYOLS, alongside sorbitol (E420), mannitol (E421), isomalt (E953), maltitol (E965) and xylitol (E967), and Group IV carries its own quantum satis authorisation across roughly 30 food categories (energy-reduced or no-added-sugar foods) under Reg (EU) No 1129/2011. EFSA re-evaluation Dec 2023 established an ADI of 0.5 g/kg bw/day and declined to remove the laxative warning required for foods containing more than 10% erythritol.

Which Part Does What

Monk fruit extract is a high-intensity sweetener. FDA puts it at 100 to 250 times sweeter than sugar depending on its mogroside V content, which runs from 2% to 95% between grades, and labels almost never say which grade is in the tub. Used at milligram levels, it adds no volume, structure, browning or mouthfeel.

Erythritol is a bulk sweetener, a sugar alcohol at 60–80% of sugar’s sweetness. It provides everything the extract cannot: the weight, the volume and the spoon-for-spoon feel. It also brings its own traits. It has the strongest cooling effect of the common sugar alcohols, it does not brown, and it recrystallizes as foods cool, which leaves baked goods and frozen desserts gritty.

The practical rule follows: judge a “monk fruit” blend by its bulking agent, because that is where its carbohydrate, its digestive ceiling and its cooling effect come from.

Calories and Blood Sugar

Erythritol has a 0 kcal/g factor from FDA, the only sugar alcohol with one, and a glycemic index of 0 across four studies. Its grams count in Total Carbohydrate on a US label but not in Total or Added Sugars, and they subtract in full from net carbs.

No authority has assigned monk fruit extract a caloric factor; at the milligram amounts people eat, its contribution is negligible. Its one published human trial, 30 healthy men given one drink each, found no meaningful glucose or insulin spike. No trial has tested monk fruit sweetener in people with diabetes, even though FDA’s modeling found children with diabetes have the highest average intake of any group.

Intake Limits

Both now have an acceptable daily intake, and neither is a comfortable margin.

Erythritol’s comes from the gut. EFSA pooled ten human studies with diarrhea thresholds of 0.5 to 1 g per kg of body weight in a single dose, and in 2023 set an ADI at the low end, 0.5 g/kg a day. It found children’s high intakes already exceed it, and the EU requires a laxative warning on foods with more than 10% erythritol. For a 70 kg adult, a single 30 g serving is about 86% of the daily limit, and in a tub that is mostly erythritol, most of every gram counts toward it.

Monk fruit’s is temporary. In 2026 JECFA set 0–10 mg per kg of body weight a day, as mogroside V, and in the same evaluation estimated children’s exposure under proposed international uses at about four times that, which it called a potential safety concern. That estimate is built on proposed uses rather than measured intakes; FDA’s modeling of US use is far lower, with children with diabetes highest at an average of 1.52 mg/kg a day. JECFA wants a reproductive toxicity study and revised proposed uses by the end of 2029. Behind this sits EFSA’s 2019 finding that the toxicity data were insufficient, including a 90-day rat study with decreased testis weight that “cannot be ruled out” as adverse: an incomplete file, not a demonstrated harm.

The Cardiovascular Question

Erythritol carries a research question that monk fruit does not. A 2023 study in Nature Medicine linked higher blood erythritol to a higher risk of major adverse cardiac events. The ARIC study of 4,006 older adults linked it to heart-failure hospitalization, cardiovascular death and death from any cause, and three genetic studies published in 2025 and 2026 found higher genetically predicted erythritol going with higher odds of stroke or coronary disease.

All of these measure erythritol in the blood, which the body also makes from glucose, not erythritol in the diet. In the Nurses’ Health Study the association faded once diabetes was accounted for, while a same-size signal for mannitol and sorbitol, polyols almost nobody eats in quantity, did not. FDA’s review of the 2023 study noted it did not adjust for kidney function. No regulator has restricted erythritol; the signal is real, unresolved and still moving.

Regulatory Status

In the US both are GRAS by notification: six FDA “no questions” letters for monk fruit extracts (2010–2017) and six for erythritol (2001–2026). Neither letter is a formal FDA approval.

In the EU they diverge. Erythritol is authorized as E 968 under the group authorization for polyols. Monk fruit extract is a novel food with no authorization, and EFSA could not establish an ADI for it as an additive in 2019; only traditional monk fruit decoctions are exempt from needing authorization.

Which Should You Choose

If you want sweetness without bulk, for drinks or sauces, pure monk fruit extract (or a liquid) avoids erythritol’s digestive load and cooling entirely. If you need bulk, for baking or spooning, you are choosing erythritol, whatever the front of the tub says; keep its daily limit in mind, and note that it will not brown. If you would rather avoid erythritol, check the ingredient list of any “monk fruit” product before assuming it is mostly monk fruit.

The Bottom Line

Monk fruit and erythritol are usually partners in one tub, and the comparison matters because each half carries its own unresolved question. Monk fruit extract is used in tiny amounts, with no caloric or glycemic load worth counting, but its only ADI is temporary and its safety evaluation is unfinished. Erythritol is the bulk you actually eat, with a zero-calorie, zero-GI profile, a digestive limit lower than most people assume, and a cardiovascular association that is real but not shown to come from diet.

// Sourced record

Monk Fruit — the checked figures

Preliminary Reviewed 27 Oct 2026 Next review 31 Dec 2026

A sugar substitute cannot treat a low blood glucose

Low blood glucose is below 70 mg/dL. The ADA's stated rule is 15 grams of FAST-ACTING carbohydrate, then recheck after 15 minutes — none of the substitutes on this site qualify, because not raising blood glucose is the entire point of them. Severe hypoglycaemia is an emergency needing help from others; if someone is unconscious and glucagon is unavailable or nobody knows how to use it, call 911. Your own care plan takes priority over anything written here.

American Diabetes Association clinical guidance checked 31 Aug 2026

Sweetness: 100–250× sweeter than sugar A MULTIPLE, not a fraction — see the header warning. CORRECTED 2026-08-30 from an earlier 100-400 band: FDA gives 100-250 for the EXTRACT ("SGFE, depending on the mogroside content, is reported to be 100 to 250 times sweeter than sugar"), while the ~250 figure in the literature describes PURE mogroside V. Those are not in conflict once you separate extract from active compound, and the extract figure is the one that matters commercially. Potency tracks mogroside V content, which varies 2%-95% between grades. US Food and Drug Administration regulatory checked 30 Aug 2026
Active compound content: 2–95% mogroside V, depending on grade Nine distinct product grades in a single GRAS notice (GRN 629): 2%, 18-23%, 24-27%, 40%, 45%, 50%, 60%, 90%, 95% mogroside V, separated by successive resin and chromatography steps. Across GRNs 301/359/522/556 the range is 12.5-90%. The label almost never states which grade is in the tub. US FDA GRAS Notice Inventory regulatory checked 30 Aug 2026
Calories: negligible at use levels Deliberately not stated as "0 kcal/g". No authority has assigned monk fruit extract a caloric factor the way FDA assigned erythritol 0 and allulose 0.4. What is documented is the exposure: mean SGFE intake up to 1.6 mg/kg bw/day, 90th percentile 4.2 mg/kg bw/day in healthy adults. US FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026
Net carbs: Subtracts in full — none of its grams count Applies to the EXTRACT ONLY. Reported mean dietary exposures are 0.58-1.52 mg/kg bw/day of mogroside V depending on subpopulation — milligrams, against grams for a bulk sweetener. For a retail blend, compute the carbohydrate from the bulking agent and treat the monk fruit as zero. US FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026 "Net carbs" is not a recognised measure — start from Total Carbohydrate The American Diabetes Association is explicit: the term "does not have a legal definition and is not used by the Food and Drug Administration or recognized by American Diabetes Association", and the FDA recommends using total carbohydrates on the label. Their reasoning applies directly to the subtraction this site performs: it assumes fibre and sugar alcohols are not absorbed or metabolised, "but this is not always true, and some are partially digested and therefore still provide calories as well as impact blood glucose" — and because the label does not say WHICH sugar alcohol is present, the effect on blood glucose "cannot be determined precisely". Treat the figure above as a formulation aid, not a carbohydrate count to dose insulin against. American Diabetes Association clinical guidance checked 31 Aug 2026
Glycemic response: No meaningful glucose or insulin spike in healthy adults, acutely Tey et al. 2017, the only published human RCT of monk fruit sweetener itself (as opposed to its regulatory toxicology). 30 healthy men, randomised crossover, four 65 g-sucrose-equivalent preloads (aspartame, monk fruit, stevia, sucrose). Monk fruit, stevia and aspartame all produced significantly lower postprandial glucose and insulin than sucrose, with no meaningful spike above baseline for any of the three. THE MORE INTERESTING FINDING: ad libitum lunch intake after the non-nutritive-sweetener preloads was significantly HIGHER than after sucrose — compensatory eating largely offset the calories saved at the preload, leaving total daily energy intake unchanged across all four arms. Read as evidence about the preload only, not as evidence the sweetener itself changes appetite regulation days or weeks out — one meal, one measurement. Tey SL, Salleh NB, Henry J, Forde CG; International… peer reviewed checked 31 Aug 2026
Acceptable daily intake: Temporary ADI 0-10 mg/kg bw/day, as mogroside V (JECFA, 2026) JECFA, 102nd meeting (2026): "The Committee established a temporary ADI of 0-10 mg/kg bw per day, expressed as mogroside V, based on a NOAEL of 2144 mg/kg bw per day for mogroside V, the highest dose tested in a 52-week rat study and the application of a 200-fold uncertainty factor." In the same evaluation JECFA took a conservative estimate of the highest dietary exposure for children, 38 mg/kg bw/day, and concluded it "exceeds the temporary ADI by approximately four-fold, which would pose a potential safety concern under the proposed uses and proposed maximum levels". JECFA noted that estimate rests on proposed Codex (GSFA) food categories and maximum levels, not on measured intakes; FDA's modelling for US use (GRN 706, see dietary_exposure_mg_per_kg_day) is far lower, a 1.52 mg/kg bw/day mean for diabetic children. To complete the evaluation JECFA requires, by the end of 2029, a reproductive toxicity study that evaluates the reproductive capacity of the F1 generation, and revised proposed uses and maximum levels. History: JECFA put monk fruit extract on its 2016 agenda and removed it because no data were submitted; EFSA (2019) could not set an ADI because the toxicity database was insufficient (see safety_signal). JECFA (FAO/WHO) regulatory checked 27 Oct 2026
Measured intake: healthy adults 0.58 · diabetic adults 0.63 · healthy children 0.96 · diabetic children 1.52 mg/kg per day (mean) Mogroside V, per GRN 706. 90th-percentile figures are 1.53 / 2.03 / 2.24 / 2.05 for the same four groups. Diabetic children carry the highest mean exposure. US FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026
Open safety question: Unresolved testicular finding in a 90-day rat study; toxicity database judged insufficient EFSA 2019: "the toxicity database on Monk fruit extract is insufficient to conclude on the safety of the use of monk fruit extract as a food additive." Specific gaps: no chronic/carcinogenicity study despite mogroside V being systemically bioavailable; in vitro genotoxicity insufficient to cover microbial-degradation metabolites including the aglycone; male exposure in the reproductive screening study "did not cover the full length of spermatogenesis"; and a 90-day rat study showed decreased testis weight with histopathological findings that "cannot be ruled out" as adverse. This is an incomplete dossier, not a demonstrated harm. EFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 30 Aug 2026
Bulk contribution: none High-intensity sweetener used at milligram levels; contributes no volume, structure, browning or mouthfeel. Any product that fills a measuring cup is doing so with something else. This is why tabletop "monk fruit" is usually a blend. US FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026
United States: GRAS by notification Six "no questions" letters: GRN 301 (15 Jan 2010), 359 (11 Apr 2011), 522 (8 Dec 2014), 556 (5 Nov 2015), 629, and 706 (17 Aug 2017). FDA is explicit that such a letter "is not an affirmation that SGFE is GRAS under 21 CFR 170.35". Intended use excludes infant formula. US FDA, Office of Food Additive Safety regulatory checked 30 Aug 2026
European Union: Not authorised as a food; only decoctions are exempt from needing authorisation CORRECTED 2026-08-31 by two independent sessions running concurrently, reconciled here after a file-write race. This record previously said "Partially authorised", citing Commission Implementing Regulation (EU) 2024/2345 of 7 October 2024 as having authorised an aqueous monk fruit extract as a novel food, taken from Kaim 2025 (a peer-reviewed review). THAT IS WRONG, and it was wrong in the paper it came from. WHAT IS ACTUALLY TRUE, per the European Commission Novel Food Catalogue entry for Siraitia grosvenorii (updated 3 October 2024, source eucatalogue): the FRUIT and its extracts are classified NOVEL FOOD — "not consumed in the EU to a significant degree as a food before 15 May 1997", so "a pre-market authorisation in accordance with Regulation (EU) 2015/2283 is required before it can be placed as food on the EU market" — and no such authorisation has been granted. SEPARATELY, monk fruit DECOCTIONS are classified NOT NOVEL, following a determination by the Irish competent authority (FSAI) under Commission Implementing Regulation (EU) 2018/456, on the basis that decoctions were consumed in the Union before 15 May 1997. A not-novel determination means authorisation is NOT REQUIRED for decoctions specifically; it is not itself an authorisation, and it does not cover purified mogroside V or solvent extracts. Likely origin of the error: the decoction not-novel determination was catalogued in early October 2024 and got telescoped, somewhere in the citation chain, into an "authorising regulation of 7 October 2024" for the extract. Independently corroborated five ways: (1) the ELI lookup for reg_impl:2024:2345:oj returns "No results found"; (2) document number 2024/2345 does resolve on EUR-Lex, but to an unrelated OJ C-series item — a European Investment Bank Deputy Chief Executive vacancy notice published 21 March 2024 — with zero mention of Siraitia, monk fruit or novel food, which is why CELEX 32024R2345 (R for Regulation) 404s; (3) an EUR-Lex advanced search of every Commission Implementing Regulation published in October 2024 returns zero matches for "Siraitia" (the two novel-food authorisations that month were vitamin D2 mushroom powder and magnesium L-threonate); (4) the consolidated Union list of novel foods (Reg (EU) 2017/2470) contains zero occurrences of "Siraitia", "grosvenorii", "monk fruit" or "mogroside" — checked by full-text search of the entire consolidated Annex across three separate consolidated versions (2024-11-07, 2026-07-02, 2026-08-10 — see unionlist2026), with presence checks on known unrelated entries (astaxanthin, krill, chia) confirming each render was complete, not truncated; (5) kaim2025's own bibliography entry for the regulation cites "Off. J. Eur. Union. 2024;L 279:25–28", and that citation also fails to resolve on EUR-Lex ("the requested document does not exist") — the paper cites no distinct EFSA reference for the "2024 EFSA opinion" it says underpins the authorisation either; its footnotes for that claim point only to the 2019 additive opinion and an FSAI page about decoction status. Practical position: monk fruit EXTRACT cannot lawfully be placed on the EU market as a food — neither via the additive route (EFSA found the 2019 toxicology dossier insufficient; no ADI) nor via the novel-food route (no authorisation exists). A DECOCTION is a different product with a different, more permissive answer. The claim of a further additive application accepted for EFSA assessment with public consultation opened April 2026 is retained from kaim2025 but was NOT independently re-verified this pass — treat it as less solid than the findings above, which are. European Commission, Directorate-General for Health and Food Safety —… regulatory checked 31 Aug 2026

Where this leaves it

The cleanest label story of the three and the thinnest safety file. It is plant-derived, used in milligrams, and carries no caloric or glycaemic load worth counting — but its only ADI is a temporary one JECFA set in 2026, which JECFA's own conservative estimate of children's exposure under proposed Codex uses exceeds about four-fold; no EU authorisation of any monk fruit extract could be confirmed against primary law despite a widely-repeated claim to the contrary (see eu_status); and an unresolved testicular finding sits in the record because the toxicology dossier is still incomplete.

What you buy in a tub labelled "monk fruit" is usually mostly a bulking agent by weight. Judge that product by its bulking agent — very often erythritol — because that is where its carbohydrate, its digestive ceiling and its cooling effect actually come from.

If you're managing diabetes

No published trial has tested monk fruit sweetener in people with diabetes specifically — despite diabetic children showing the highest modelled exposure of any group FDA looked at.

FDA's own exposure modelling in GRN 706 found diabetic children carry the highest mean mogroside V intake of any subgroup assessed (1.52 mg/kg bw/day, against 0.58 for healthy adults) — the population already consuming it most is exactly the one with no dedicated clinical trial behind it. The only human RCT of the sweetener itself (Tey 2017) tested 30 healthy men, not people with diabetes, and found no meaningful glucose or insulin spike from monk fruit, stevia or aspartame versus sucrose. Two things this record already flags matter more here than usual: the only ADI is JECFA's temporary 2026 one, which JECFA's conservative estimate of children's exposure under proposed Codex uses exceeds about four-fold (see adi_status), and what you buy in a tub is usually mostly a bulking agent by weight, very often erythritol — read that record's diabetes note for what you're actually eating in bulk.

US FDA, Office of Food Additive Safety regulatory checked 31 Aug 2026

What would change this: A genuine novel-food application for the extract being filed and reaching a decision, or the EFSA additive assessment reportedly opened to consultation in April 2026 (itself unverified this pass) reaching a conclusion; or the reproductive toxicity study (F1 reproductive capacity) and revised proposed uses that JECFA requires by the end of 2029 to complete its 2026 evaluation and decide whether its temporary ADI stands.

No sweetener here is established to improve long-term health ADA Standards of Care 2026, Section 5: "NNS do not appear to have a significant effect on glycemic management," and evidence on weight is mixed — some reviews find modest weight-loss benefit, others an association with weight gain, likely reflecting reverse causation and confounding; added to an eating plan without energy restriction, NNS show no weight benefit. Substituting can reduce sugar and calories. That is a different claim from improving an outcome, and only the first is supported. CORROBORATED 2026-08-31 at much larger scale: Jeong et al.'s umbrella review (29 meta-analyses, 24 observational studies plus 6 RCTs, 50M+ participants, 135 associations examined) found observational studies link higher sweetener intake to INCREASED risk of weight gain, metabolic syndrome, type 2 diabetes and hypertension, while RCTs show only modest weight-loss benefit versus sugar specifically. The two study designs are not measuring the same comparison — see the general-health page for why — but neither supports a durable, independent long-term health benefit, which is the ADA position this guardrail already states. American Diabetes Association Professional Practice Committee for Diabetes; Diabetes… clinical guidance checked 31 Aug 2026

Every figure above links to the document it came from and carries the date we last opened that document. Where a figure has no source it is not shown at all, rather than stated without one. Tell us if you find one that is wrong.

// Sourced record

Erythritol — the checked figures

Suggestive Reviewed 23 Oct 2026 Next review 31 Jan 2027

A sugar substitute cannot treat a low blood glucose

American Diabetes Association clinical guidance checked 31 Aug 2026

Sweetness: 60–80% of sugar Specification band. Measured potency is concentration-dependent: 0.72 / 0.75 / 0.84 against 5 / 10 / 15% w/v sucrose (Wee 2018); 0.50-0.78 across 3-20% (Fujimaru 2012). EFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026
Calories: 0 kcal per gram Electronic Code of Federal Regulations regulatory checked 29 Aug 2026
Net carbs: Subtracts in full — none of its grams count FDA assigns erythritol 0 cal/g, uniquely among polyols (all others 2.0-3.0). Glycaemic index 0. Electronic Code of Federal Regulations regulatory checked 29 Aug 2026 "Net carbs" is not a recognised measure — start from Total Carbohydrate The American Diabetes Association is explicit: the term "does not have a legal definition and is not used by the Food and Drug Administration or recognized by American Diabetes Association", and the FDA recommends using total carbohydrates on the label. Their reasoning applies directly to the subtraction this site performs: it assumes fibre and sugar alcohols are not absorbed or metabolised, "but this is not always true, and some are partially digested and therefore still provide calories as well as impact blood glucose" — and because the label does not say WHICH sugar alcohol is present, the effect on blood glucose "cannot be determined precisely". Treat the figure above as a formulation aid, not a carbohydrate count to dose insulin against. American Diabetes Association clinical guidance checked 31 Aug 2026
Glycemic index: 0 (glucose = 100) Mean 0, SD 17 across 4 studies (glucose = 100). Insulinaemic index 2. The SD is large relative to the mean: this is "no detectable effect", not a precise zero. Livesey G, Nutrition Research Reviews 16:163-191 peer reviewed checked 29 Aug 2026
Counts in Total Carbohydrate (US): Yes Electronic Code of Federal Regulations regulatory checked 29 Aug 2026
Counts in Total Sugars (US): No Total Sugars is the sum of free mono- and disaccharides; polyols are not included. Electronic Code of Federal Regulations regulatory checked 29 Aug 2026
Counts in Added Sugars (US): No Electronic Code of Federal Regulations regulatory checked 29 Aug 2026
Sugar alcohol line: when_claimed Voluntary by default; mandatory whenever a claim about sugar alcohol, total sugars or added sugars appears on the label. 21 CFR 101.9(c)(6)(iv). Electronic Code of Federal Regulations regulatory checked 29 Aug 2026
Digestive tolerance: 0.5–1 g/kg in one sitting · EU limit 0.5 g/kg per day EFSA pooled NOAELs for diarrhoea from 10 human studies: range 0.51-1.0 g/kg bw, median 0.75. EFSA adopted the lower bound, 0.5 g/kg bw/day, as its first numerical ADI for erythritol (Dec 2023) and found children's 95th-percentile intake already exceeds it. EFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026
Cardiovascular evidence: Consistently associated; causation unestablished; the weight has shifted toward biomarker rather than cause UPDATED 2026-08-31 with two sources that shift the reading toward BIOMARKER and away from dietary harm — recorded that way despite being commercially convenient, because they are what the evidence says. (1) NURSES' HEALTH STUDY (Heianza 2024, 762 cases / 762 controls, 11-16y): erythritol RR 1.15 (1.04-1.28) per SD for incident CHD — but it ATTENUATED TO NON-SIGNIFICANCE once diabetes was added to the model. In the same cohort MANNITOL/SORBITOL ran 1.16 (1.05-1.28) and STAYED significant after that adjustment. Mannitol and sorbitol are not consumed at anything like erythritol's scale, so a shared signal across all three polyols points at something the body is doing rather than something people are eating. The authors say it directly: baseline blood predates erythritol's approval as a food additive, so NHS associations "might be mainly driven by endogenous erythritol". (2) FDA's OWN REVIEW of the Witkowski paper (memo, 15 June 2023) reaches the same place and adds a confounder nobody else names — KIDNEY FUNCTION WAS NOT ADJUSTED FOR, and since the kidneys excrete erythritol, impaired function raises levels independently of diet. FDA also notes the cohort was selected for existing cardiovascular risk, which limits extrapolation to healthy people, and that across thirty years of toxicological study "erythritol has consistently been shown to be safe". None of this makes the signal disappear. ARIC (n=4,006 older adults free of CVD, median 8.4y): erythritol HR 1.18 (1.07-1.30) heart-failure hospitalisation, 1.21 (1.08-1.35) cardiovascular death, 1.19 (1.12-1.28) total mortality — and erythroNATE, a related metabolite, ran stronger still at HR 1.79 (1.50-2.14) for CV death. ARIC did not measure erythritol CONSUMPTION. Against that, a 2025 Cardiovascular Research review concludes "a direct causal relationship between their use and CV events is lacking", citing null MR and ICU patients given up to 120 g/day of intravenous xylitol without attributable harm. But a separate 2025 MR reports POSITIVE associations (CHD OR 1.077, ischaemic stroke 1.157, DVT 1.117) — while also stating internally that it found "no reliable evidence" for a causal VTE link, and resting on a small 8,167-person exposure GWAS. ADDED 2026-10-23: a further MR published 31 August 2026 (Zhong 2026, International Journal of Molecular Sciences) reports genetically predicted circulating erythritol associated with ischaemic stroke, OR 1.246 (1.101-1.410), and still associated after multivariable adjustment for blood pressure, type 2 diabetes/HbA1c and LDL/triglycerides (systolic pressure, type 2 diabetes and LDL together: OR 1.395, 1.155-1.686). It rests on 34 genetic instruments from a European-ancestry exposure GWAS whose sample size the paper gives only in its supplement, and its authors state that the instruments "cannot distinguish whether these concentrations arise from dietary intake" and that the result "should not be interpreted as direct evidence that dietary erythritol intake causes stroke". ADDED 2026-10-27: a third positive MR, which predates Zhong (Fan 2025, American Journal of Preventive Cardiology, published 6 October 2025), reports genetically predicted erythritol associated with coronary heart disease OR 1.0020 (1.0007-1.0034), myocardial infarction 1.0015 (1.0004-1.0026) and stroke 1.0463 (1.0010-1.0937), and no association with heart failure or diabetes. Its exposure rests on a GWAS of only 291 people, the other MR methods were non-significant though pointing the same way, the per-unit effects are very small, and the authors describe the evidence as genetic evidence of association. Three MR studies now point toward harm and one review cites null MR. Unresolved, and moving. Abushamat LA, Yu B, Hoogeveen RC et al.; JACC:… peer reviewed checked 27 Oct 2026
Browning: none Polyols do not participate in Maillard browning; the additive specification caps reducing substances at 0.3% as D-glucose. European Commission regulatory checked 29 Aug 2026
Bulk contribution: bulking Used as a bulk sweetener, but a 1:1 weight swap under-sweetens because it delivers only 60-80% of sucrose sweetness. EFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026
Recrystallisation: high Low solubility relative to sucrose; recrystallises on cooling, which is the mechanism behind the gritty or sandy texture in baked goods and frozen desserts. Tyapkova et al. peer reviewed checked 29 Aug 2026
Cooling effect: 3 Strongest cooling of the common polyols. Endothermic dissolution, enthalpy of solution approximately +22 to +24 kJ/mol. Perceived intensity is lower than the raw figure suggests because erythritol is less soluble than xylitol. Tyapkova et al. peer reviewed checked 29 Aug 2026
United States: GRAS by notification Six FDA "no questions" letters, per FDA's GRAS Notice Inventory (checked 2026-10-27): GRN 76 (closed 2001-09-11), 208 (2007-01-25), 382 (2011-11-21), 401 (2012-03-22), 789 (Cargill, 2019-02-20) and 1296 (Shandong Starlight So True, 2026-04-07), the last for erythritol "produced through fermentation of glucose by Yarrowia lipolytica". CORRECTED 2026-10-27: this note previously said six letters ran from GRN 76 through GRN 789, which is five. The production organism now varies by supplier, so prose naming only Moniliella is incomplete. Intended uses in GRN 1296 exclude infant formula and USDA-regulated products. US Food and Drug Administration regulatory checked 27 Oct 2026
European Union: Authorised, E 968 VERIFIED DIRECTLY against the EU Food Additives register, 2026-08-31 — do not confuse the two authorisation layers. The substance-specific listing for erythritol shows only ONE category (14.1.4, flavoured drinks, as a flavour enhancer, ML 16000 mg/l, energy-reduced/no-added-sugar only, under Reg (EU) 2015/1832) — reading only that would wrongly suggest erythritol is authorised for almost nothing. The real authorisation is broader: erythritol is a member of GROUP IV, POLYOLS, alongside sorbitol (E420), mannitol (E421), isomalt (E953), maltitol (E965) and xylitol (E967), and Group IV carries its own quantum satis authorisation across roughly 30 food categories (energy-reduced or no-added-sugar foods) under Reg (EU) No 1129/2011. EFSA re-evaluation Dec 2023 established an ADI of 0.5 g/kg bw/day and declined to remove the laxative warning required for foods containing more than 10% erythritol. EFSA Panel on Food Additives and Flavourings, EFSA Journal… regulatory checked 29 Aug 2026

Where this leaves it

No regulator has restricted it, but the cardiovascular question is open and the digestive limit is real and lower than most people assume.

A single 30 g serving is about 86% of the EU daily intake limit for a 70 kg adult — and 30 g is the dose that raised platelet reactivity in the 2024 trial.

If you're managing diabetes

Does not move blood glucose by any figure in this record — but the digestive tolerance ceiling is closer than it looks, and diabetes is the exact variable that weakens the strongest cardiovascular signal.

Glycaemic index 0, subtracts in full from net carbs — nothing here requires carbohydrate coverage. The tolerance figure above is the one to watch: a single 30 g serving is about 86% of the EU daily limit for a 70 kg adult (see this record's verdict caveat). Separately, and worth knowing rather than reassuring: in the Nurses' Health Study, erythritol's association with coronary heart disease attenuated to non-significance specifically once diabetes was added to the statistical model — while the same-magnitude signal for mannitol and sorbitol, eaten at nowhere near erythritol's scale, stayed significant. That does not clear erythritol; it means diabetes status is the specific variable behind whether the strongest available human evidence for a heart-risk association survives adjustment, in a population managing a condition that already elevates cardiovascular risk on its own.

Heianza Y, Sun Q, Manson JE et al.; European… peer reviewed checked 31 Aug 2026Declared interest: Three authors hold equity or executive positions at Sapient Bioanalytics, the metabolomics company; one holds an NIH grant. Declared and displayed.

What would change this: A trial measuring cardiovascular outcomes against dietary erythritol intake rather than plasma concentration, or a Commission response to the 2023 EFSA ADI.

New comparisons and corrections, as they land.

This page is educational information, not medical or dietary advice. Nutrition and regulatory details change over time — verify against the cited primary sources before relying on them for formulation or health decisions.